title: Serum miR-128-2 serves as a prognostic marker for patients with hepatocellular carcinoma.
abstract: Circulating miRNAs are promising biomarkers for predicting the aggressiveness of hepatocellular carcinoma (HCC). We aimed to identify differentially expressed miRNAs in the serum of HCC patients with different Barcelona Clinic Liver Cancer (BCLC) stage, and to investigate the potential of serum miRNAs as biomarkers for patient outcomes. In the discovery stage, TaqMan Low-Density Array was used to test the difference in levels of serum miRNAs between 20 patients with portal vein tumor thrombosis (PVTT) and 20 patients without PVTT. The detected serum miRNAs then were validated in 182 patients. Fifteen serum miRNAs showed more than two-fold higher expression in patients with PVTT, and miR-128-2 was found to be significantly up-regulated and was selected for further validation. In the validation stage, patients were divided into two groups with low or high serum miR-128-2 using the median expression level of all 182 cases as the cut-off point. Kaplan-Meier analysis revealed that patients with low level of serum miR-128-2 had favorable trends of survival (log rank = 13.031, p < 0.001). The median survivals for patients with a low and high level of serum miR-128-2 were 625 (95% CI, 527-722) days and 426 (95% CI, 362-491) days, respectively. MiR-128-2 was also an independent factor of overall survival (p = 0.001, HR 2.793, 95%CI 1.550, 5.033). Serum levels of the ubiquitously expressed miR-128-2 showed no significant correlation with parameters of liver damage or liver function. In addition, expressions of miR-128-2 in HCC tissues were up-regulated in comparison with adjacent non-tumor tissues. In conclusion, serum level of miR-128-2 serves as a noninvasive biomarker for the overall survival of patients with hepatocellular carcinoma.
authors: Department of Integrative Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
authors: Liping
authors: L
authors: Zhuang
authors: Department of Integrative Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
authors: Litao
authors: L
authors: Xu
authors: Department of Integrative Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
authors: Peng
authors: P
authors: Wang
authors: Department of Integrative Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
authors: Zhiqiang
authors: Z
authors: Meng
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood* / Q000235:genetics; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000150:complications / Q000175:diagnosis* / Q000235:genetics; D015331:Cohort Studies; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood* / Q000150:complications / Q000175:diagnosis* / Q000235:genetics; D008297:Male; D035683:MicroRNAs / Q000097:blood* / Q000235:genetics; D008875:Middle Aged; D011169:Portal Vein; D011379:Prognosis; D015854:Up-Regulation; D020246:Venous Thrombosis / Q000150:complications
chemical_list: D014408:Biomarkers, Tumor; C545189:MIRN128 microRNA, human; D035683:MicroRNAs
references: Hepatology. 2011 Mar;53(3):1020-2
references: 21374666
references: PLoS One. 2010;5(6):e10748
references: 20574517
references: Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8
references: 16039986
references: Hepatology. 2011 Aug;54(2):463-71
references: 21538440
references: Cell Mol Life Sci. 2011 Apr;68(8):1415-28
references: 20924637
references: Cancer Res. 2010 Jun 1;70(11):4528-38
references: 20460539
references: Cancer Res. 2010 Dec 1;70(23):9798-807
references: 21098710
references: Cell Res. 2008 Oct;18(10):997-1006
references: 18766170
references: Cancer. 1990 Nov 15;66(10):2174-9
references: 2171748
references: FASEB J. 2009 Dec;23(12):4276-87
references: 19713529
references: Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61
references: 16461460
references: Nature. 2005 Jun 9;435(7043):834-8
references: 15944708
references: J Cell Biochem. 2006 Oct 15;99(3):671-8
references: 16924677
references: Hepatology. 2010 May;51(5):1614-23
references: 20209605
references: World J Surg. 2005 Nov;29(11):1374-83
references: 16240064
references: J Biol Chem. 2008 May 9;283(19):13205-15
references: 18319255
references: J Hepatol. 2012 Feb;56(2):389-96
references: 21888875
references: J Clin Oncol. 2011 Dec 20;29(36):4781-8
references: 22105822
references: PLoS One. 2011;6(12):e28486
references: 22174818
references: J Clin Oncol. 2010 Jun 10;28(17):2889-95
references: 20458042
references: World J Gastroenterol. 2001 Aug;7(4):445-54
references: 11819809
references: Oncogene. 2010 Mar 25;29(12):1787-97
references: 20023698
references: Hepatology. 2009 Aug;50(2):490-9
references: 19472311
references: Cancer Cell. 2012 Sep 11;22(3):291-303
references: 22975373
references: N Engl J Med. 2009 Oct 8;361(15):1437-47
references: 19812400
references: Cell. 2004 Jan 23;116(2):281-97
references: 14744438
references: Oncogene. 2008 Sep 25;27(43):5651-61
references: 18521080
references: Hepatogastroenterology. 2007 Mar;54(74):499-502
references: 17523307
references: Gastroenterology. 2007 Aug;133(2):647-58
references: 17681183
references: J Hepatol. 2012 Feb;56(2):488-9
references: 21798220
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: Mol Carcinog. 2011 Feb;50(2):136-42
references: 21229610
references: Ann Surg Oncol. 2013 Nov;20(12):3747-53
references: 23800896
references: J Cancer Res Clin Oncol. 2011 Jan;137(1):139-49
references: 20340033
references: Ann Surg Oncol. 2010 Aug;17(8):2073-80
references: 20131013
references: Hepatology. 1989 Jan;9(1):110-5
references: 2461890
references: N Engl J Med. 2011 Sep 22;365(12):1118-27
references: 21992124